Company / EPS (Basic)
Spyre Therapeutics, Inc. EPS (Basic) History
FY2022-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$25.02
FY2023
5-year range
-$25.02 / -$1.52
FY2022-FY2023
Trend
-1546.1%
vs FY2022
Sector context
#209 of 208
Health Care
What the data says
Among 208 Health Care companies, Spyre Therapeutics, Inc. is in the bottom 0% for eps (basic).
Based on SEC 10-K filings.
-25.02 in FY2023.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 208This company -$25.02 Sector average -$0.87
▼
-2773.8% below sector average
Key checks
Key Insights
- In FY2023, eps (basic) decreased 1546.1% year-over-year.
- Ranks #209 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$25.02 | -1546.1% |
| FY2022 | -$1.52 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026